Logo Geneseeq
  • Products
    • Solid Tumors
      • Pan-Cancer
      • Cancer Type-Specific
      • Minimal Residual Disease
    • Hematologic Malignancies
      • Pan-Cancer
      • Cancer Type-Specific
    • Cancer Early Detection
    • Hereditary Cancers
  • Services
    • Central Lab Testing
    • Local Testing Solutions
      • IVD Kit Solutions
      • RUO Kit Solutions
    • Research Services
      • DNA Sequencing
      • RNA Sequencing
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
    • Newsroom
    • Geneseeq Blogs
  • Join Us
  • Contact Us
  • Search

September 29, 2025

Geneseeq Validates Cell-free DNA Blood Test for Early Detection of Pancreatic Cancer in a Prospective Study

by GENESEEQ

May 28, 2025

Geneseeq’s Breakthrough Cancer Detection Blood Test Published in Nature Medicine

by GENESEEQ

May 21, 2025

Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025

by GENESEEQ

May 7, 2025

Geneseeq Unveils Groundbreaking Blood Test for Early Detection of Pancreatic Cancer

by GENESEEQ

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

by GENESEEQ

November 15, 2022

Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM

by GENESEEQ

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info@geneseeq.ca

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2026 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences

    FDA Cleared IVD kit